Sugi Predict

Sugi Predict / Compounds / Phenpromethamine

Phenpromethamine

Phenpromethamine

SCHEMBL3958676

CNC[C@@H](C)c1ccccc1

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 3/20 0.95
▸ AOC3 Q16853 2/20 0.65
▸ HTR2A P28223 2/20 0.50
▸ HRH1 P35367 2/20 0.50
▸ TRPA1 O75762 2/20 0.47
▸ RIPK1 Q13546 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SLC6A2 P23975 7/20 0.46
▸ SLC6A4 P31645 7/20 0.46
▸ SLC6A3 Q01959 5/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ KCNH2 Q12809 1/20 0.44
▸ GRIA4 P48058 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenpromethamine SCHEMBL4917327 1.00 TAAR1 (0.95) TAAR1AOC3HTR2AHRH1TRPA1
SCHEMBL23783575 1.00 TAAR1 (0.95) TAAR1AOC3HTR2AHRH1TRPA1
Phenpromethamine SCHEMBL681384 1.00 TAAR1 (0.95) TAAR1AOC3HTR2AHRH1TRPA1
Phenpromethamine SCHEMBL6235704 0.98 TAAR1 (1.00) TAAR1AOC3HTR2AHRH1TRPA1
Phenpromethamine SCHEMBL28235619 0.88 TAAR1 (0.75) TAAR1AOC3HTR2AHRH1TRPA1
SCHEMBL11046082 0.83 TAAR1 (0.68) TAAR1AOC3TRPA1RIPK1NPC1
SCHEMBL24287871 0.81 TAAR1 (0.66) TAAR1AOC3HTR2AHRH1TRPA1
SCHEMBL1908636 0.80 TAAR1 (0.64) TAAR1AOC3HTR2AHRH1SLC6A2
SCHEMBL13164306 0.79 TAAR1 (0.63) TAAR1AOC3TRPA1RIPK1NPC1
SCHEMBL12000667 0.79 TAAR1 (0.63) TAAR1AOC3TRPA1RIPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 — — US disclosed
US-9212202-B2 Methods of peptide modification LYTIX BIOPHARMA AS (NO) 2015-12-15 — — US disclosed
US-9212202-B2 Methods of peptide modification LYTIX BIOPHARMA AS (NO) 2015-12-15 — — US disclosed
US-20150073136-A1 PYRAZINONE DERIVATIVES ASTRAZENECA AB (SE) 2015-03-12 — — US disclosed
US-8889692-B2 Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses ASTRAZENECA AB (SE) 2014-11-18 — — US disclosed
EP-2170848-B1 PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES ASTRAZENECA AB (SE) 2014-10-22 — — EP disclosed
US-8193175-B2 Ruthenium complexes for treating cancers UNIVERSITE DE STRASBOURG (FR) 2012-06-05 — — US disclosed
US-20110143384-A1 METHODS OF PEPTIDE MODIFICATION LYTIX BIOPHARMA AS (NO) 2011-06-16 — — US disclosed
US-20110143384-A1 METHODS OF PEPTIDE MODIFICATION LYTIX BIOPHARMA AS (NO) 2011-06-16 — — US disclosed
EP-1776103-B1 RUTHENIUM COMPLEXES FOR TREATING CANCERS UNIV STRASBOURG (FR) 2009-07-08 — — EP disclosed
US-20080146612-A1 Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor ASTRAZENECA AB (SE) 2008-06-19 — — US disclosed
US-20080051370-A1 Ruthenium Complexes For Treating Cancers UNIVERSITE DE STRASBOURG (FR) 2008-02-28 — — US disclosed
US-20070203183-A1 Diaryl piperidines as CB1 modulators SCHERING CORPORATION 2007-08-30 — — US disclosed
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 — — US disclosed
EP-1776103-A1 RUTHENIUM COMPLEXES FOR TREATING CANCERS UNIVERSITE LOUIS PASTEUR (FR) 2007-04-25 — — EP disclosed
WO-2006016069-A1 RUTHENIUM COMPLEXES FOR TREATING CANCERS UNIVERSITE LOUIS PASTEUR (FR) 2006-02-16 — — WO disclosed
WO-2004080976-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2004-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203183-A1 Diaryl piperidines as CB1 modulators CNR1, CNR2, GPR119 TAAR1 42/4885AOC3 2933/4885HTR2A 140/4885
US-20080146612-A1 Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor P2RX2, P2RX1, ADORA1 TAAR1 128/4885AOC3 2359/4885HTR2A 161/4885
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR PARP3, PARP1, PARP4 TAAR1 4878/4885AOC3 4163/4885HTR2A 4347/4885
US-20070197522-A1 Dpp-iv inhibitors DPP7, DPP4, DPP3 TAAR1 2640/4885AOC3 2680/4885HTR2A 1553/4885
US-20080051370-A1 Ruthenium Complexes For Treating Cancers TP53, KRAS, HRAS TAAR1 4670/4885AOC3 3078/4885HTR2A 4781/4885
US-20110143384-A1 METHODS OF PEPTIDE MODIFICATION PTMS, RNPEP, CTRC TAAR1 2895/4885AOC3 617/4885HTR2A 2833/4885
US-20150073136-A1 PYRAZINONE DERIVATIVES CYP3A7, CYP3A4, CYP2D6 TAAR1 1677/4885AOC3 2298/4885HTR2A 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.